TR201901516T4 - Nöroprotektif ajanlar ve bunların kullanımları. - Google Patents

Nöroprotektif ajanlar ve bunların kullanımları. Download PDF

Info

Publication number
TR201901516T4
TR201901516T4 TR2019/01516T TR201901516T TR201901516T4 TR 201901516 T4 TR201901516 T4 TR 201901516T4 TR 2019/01516 T TR2019/01516 T TR 2019/01516T TR 201901516 T TR201901516 T TR 201901516T TR 201901516 T4 TR201901516 T4 TR 201901516T4
Authority
TR
Turkey
Prior art keywords
neuroprotective agents
neuroprotective
agents
androstan
triol
Prior art date
Application number
TR2019/01516T
Other languages
English (en)
Inventor
Yin Wei
Chen Jiesi
Yan Guangmei
Lu Bingzheng
Zhu Wenbo
Hu Haiyan
Qiu Pengxin
Huang Yijun
Zhang Jingxia
Original Assignee
Guangzhou Cellprotek Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangzhou Cellprotek Pharm Co Ltd filed Critical Guangzhou Cellprotek Pharm Co Ltd
Publication of TR201901516T4 publication Critical patent/TR201901516T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

Buluş, bileşik 5?-androstan-3ß,5?,6ß-triol ve bunların analoglarının yeni bir farmasötik kullanımı ile ilgilidir.
TR2019/01516T 2014-04-25 2015-04-14 Nöroprotektif ajanlar ve bunların kullanımları. TR201901516T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410170263.7A CN105012313B (zh) 2014-04-25 2014-04-25 5α‑雄甾‑3β,5,6β‑三醇及其类似物在预防或治疗低压缺氧引起的高原病中的应用

Publications (1)

Publication Number Publication Date
TR201901516T4 true TR201901516T4 (tr) 2019-02-21

Family

ID=54331734

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/01516T TR201901516T4 (tr) 2014-04-25 2015-04-14 Nöroprotektif ajanlar ve bunların kullanımları.

Country Status (22)

Country Link
US (1) US10357500B2 (tr)
EP (1) EP3135288B1 (tr)
JP (1) JP6277289B2 (tr)
KR (1) KR101873791B1 (tr)
CN (2) CN108125965B (tr)
AU (1) AU2015251359B2 (tr)
CA (1) CA2946647C (tr)
CY (1) CY1121566T1 (tr)
DK (1) DK3135288T3 (tr)
ES (1) ES2711842T3 (tr)
HR (1) HRP20190806T1 (tr)
HU (1) HUE043685T2 (tr)
IL (1) IL248424B (tr)
LT (1) LT3135288T (tr)
PL (1) PL3135288T3 (tr)
PT (1) PT3135288T (tr)
RS (1) RS58476B1 (tr)
RU (1) RU2672264C2 (tr)
SG (1) SG11201608829SA (tr)
SI (1) SI3135288T1 (tr)
TR (1) TR201901516T4 (tr)
WO (1) WO2015161747A1 (tr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11439869B2 (en) 2017-05-19 2022-09-13 Trudell Medical International Positive expiratory pressure device
CN109985049B (zh) * 2017-12-29 2022-02-22 广州市赛普特医药科技股份有限公司 5α-雄甾-3β,5,6β-三醇在制备治疗脑小血管病的药物中的应用
USD874064S1 (en) 2018-05-18 2020-01-28 Trudell Medical International Mask
USD903097S1 (en) 2018-05-18 2020-11-24 Trudell Medical International Mask
USD893806S1 (en) 2018-11-09 2020-08-18 Trudell Medical Internationl Mask and shroud
CN113318114B (zh) * 2020-02-28 2023-02-17 广州市赛普特医药科技股份有限公司 小分子化合物在治疗肺上皮细胞损伤和/或血管内皮细胞损伤介导的疾病中的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995013075A1 (en) * 1993-11-12 1995-05-18 Cell Therapeutics, Inc. Method for preventing tissue injury from hypoxia
CN101164540A (zh) * 2006-08-03 2008-04-23 中山大学 海洋甾体化合物在制备治疗神经元损伤药物中的应用
KR20190085187A (ko) * 2008-01-22 2019-07-17 아라임 파마슈티칼즈, 인크. 조직 손상 관련 질환 및 장애를 예방 및 치료하기 위한 조직 보호 펩티드 및 펩티드 유사체
US7906159B2 (en) * 2008-04-17 2011-03-15 Vivien Chou Herbal compositions and methods for enhancing vital energy and athletic performance
CN101683348B (zh) * 2008-09-23 2012-07-04 中山大学 胆甾烷-3β,5α,6β-三醇在制备神经元保护药物中的应用
CN101884638B (zh) 2010-07-09 2011-11-09 中山大学 5α-雄甾(烷)-3β,5,6β-三醇在制备神经元保护药物中的应用
CN102180928B (zh) * 2011-03-15 2013-01-16 广州市赛普特医药科技有限公司 3β,5α,6β-三羟基甾体化合物及其合成方法和应用
RU2461376C1 (ru) * 2011-05-25 2012-09-20 Государственное образовательное учреждение высшего профессионального образования "Смоленская государственная медицинская академия" Министерства здравоохранения и социального развития Российской Федерации Антигипоксантное средство

Also Published As

Publication number Publication date
US20170042909A1 (en) 2017-02-16
KR20160146878A (ko) 2016-12-21
EP3135288A4 (en) 2017-10-18
KR101873791B1 (ko) 2018-07-03
RU2672264C2 (ru) 2018-11-13
HUE043685T2 (hu) 2019-09-30
CN105012313B (zh) 2018-03-16
RS58476B1 (sr) 2019-04-30
IL248424B (en) 2020-06-30
DK3135288T3 (en) 2019-03-25
JP2017513873A (ja) 2017-06-01
AU2015251359B2 (en) 2017-10-26
PL3135288T3 (pl) 2019-07-31
RU2016141462A (ru) 2018-05-25
PT3135288T (pt) 2019-03-01
CN105012313A (zh) 2015-11-04
CA2946647C (en) 2018-10-09
HRP20190806T1 (hr) 2019-06-28
AU2015251359A1 (en) 2016-11-10
EP3135288A1 (en) 2017-03-01
JP6277289B2 (ja) 2018-02-07
US10357500B2 (en) 2019-07-23
SG11201608829SA (en) 2016-12-29
IL248424A0 (en) 2016-11-30
ES2711842T3 (es) 2019-05-07
CA2946647A1 (en) 2015-10-29
CY1121566T1 (el) 2020-05-29
CN108125965A (zh) 2018-06-08
SI3135288T1 (sl) 2019-04-30
WO2015161747A1 (zh) 2015-10-29
CN108125965B (zh) 2020-04-10
EP3135288B1 (en) 2019-01-30
RU2016141462A3 (tr) 2018-05-25
LT3135288T (lt) 2019-03-25

Similar Documents

Publication Publication Date Title
ECSP18007905A (es) Anticuerpos monoclonales contra bcma
CL2016002455A1 (es) Anticuerpos multiespecíficos.
TR201905829T4 (tr) Buzdolabı.
EA201791310A1 (ru) Химерные антигенные рецепторы к bcma
CL2015000942A1 (es) Compuestos de benceno sustituido.
EA201692219A1 (ru) Способы получения противовирусных соединений
CY1121602T1 (el) Συνθεση της κοπανλισιμπης και του διυδροχλωρικου αλατος της
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
BR112017000456A2 (pt) composições antivirais tópicas e métodos de uso das mesmas
EA201591805A1 (ru) Оксабицикло [2.2.2] кислоты - модуляторы gpr120
CY1123465T1 (el) Αντιβακτηριακες ενωσεις ευρεως φασματος
TR201901516T4 (tr) Nöroprotektif ajanlar ve bunların kullanımları.
TR201900124T4 (tr) Dispersiyon Reçineleri
EA201790627A1 (ru) СТИМУЛЯТОРЫ рГЦ
EA201691982A1 (ru) 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов
TR201910057T4 (tr) Kauçuk bi̇leşi̇mleri̇
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
CR20150417A (es) Compuestos de azetidiniloxifenilpirrolidina
DOP2017000058A (es) Derivados de tetrahidroquinolina como inhibidores del bromodominio
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
ECSP16096831A (es) Derivados de naftiridinadiona
BR112016027455A2 (pt) moduladores ppar
EA201692569A1 (ru) Полимиксины с низкой степенью замещения и композиции, их содержащие
BR112017024126A2 (pt) composições farmacêuticas e uso das mesmas